Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006;7:517–28.

CAS  PubMed  Article  Google Scholar 

Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10:293–301.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol. 2015;33:1397–406.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell. 1999;4:511–8.

CAS  PubMed  Article  Google Scholar 

Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001;7:263–72.

CAS  PubMed  Article  Google Scholar 

Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171–82.

CAS  PubMed  Article  Google Scholar 

Walsh CS. Two decades beyond BRCA1/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol. 2015;137:343–50.

CAS  PubMed  Article  Google Scholar 

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–7.

CAS  PubMed  Article  Google Scholar 

Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21.

CAS  PubMed  Article  Google Scholar 

McCabe N, Turner NC, Lord CJ, Kluzek K, Białkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66:8109–15.

CAS  PubMed  Article  Google Scholar 

Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26:3785–90.

CAS  PubMed  Article  Google Scholar 

Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim J-S, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009;1:315–22.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Williamson CT, Muzik H, Turhan AG, Zamò A, O’Connor MJ, Bebb DG, et al. ATM-deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther. 2010;9:347–57.

CAS  PubMed  PubMed Central  Article  Google Scholar 

McEllin B, Camacho CV, Mukherjee B, Hahm B, Tomimatsu N, Bachoo RM, et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for GBM therapy with temozolomide or PARP inhibitors. Cancer Res. 2010;70:545–64.

Article  CAS  Google Scholar 

Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011;103:334–46.

CAS  PubMed  Article  Google Scholar 

Nijman SMB. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett. 2011;585:1–6.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5:387–93.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Reinbolt RE, Hays JL. The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol. 2013;3:237.

PubMed  PubMed Central  Article  Google Scholar 

De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol. 2013;3:228.

PubMed  PubMed Central  Article  Google Scholar 

Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MI, et al. Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair. Nature. 2015;518:258–62.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Rubraca (rucaparib) tablets [prescribing information]. Boulder (CO): Clovis Oncology, Inc.; 2022.

Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther. 2007;6:945–56.

CAS  PubMed  Article  Google Scholar 

Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell AG, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol. 2012;30:283–8.

CAS  PubMed  Article  Google Scholar 

Rubraca (rucaparib) tablets [summary of product characteristics]. Swords, Ireland: Clovis Oncology Ireland Ltd.; 2019.

Mittica G, Ghisoni E, Giannone G, Genta S, Aglietta M, Sapino A, et al. PARP inhibitors in ovarian cancer. Recent Pat Anticancer Drug Discov. 2018;13:392–410.

CAS  PubMed  Article  Google Scholar 

Valabrega G, Scotto G, Tuninetti V, Pani A, Scaglione F. Differences in PARP inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy. Int J Mol Sci. 2021;22:4203.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wang H, Wu M, Liu H, Zhou H, Zhao Y, Geng Y, et al. Comparison of the efficacy and safety of PARP inhibitors as a monotherapy for platinum-sensitive recurrent ovarian cancer: a network meta-analysis. Front Oncol. 2021;11: 785102.

PubMed  PubMed Central  Article  Google Scholar 

Xu Y, Ding L, Tian Y, Bi M, Han N, Wang L. Comparative efficacy and safety of PARP inhibitors as maintenance therapy in platinum sensitive recurrent ovarian cancer: a network meta-analysis. Front Oncol. 2020;10: 573801.

PubMed  Article  Google Scholar 

Robillard L, Nguyen M, Harding TC, Simmons AD. In vitro and in vivo assessment of the mechanism of action of the PARP inhibitor rucaparib. Cancer Res. 2017;77(Suppl. 13):abstract 2475.

e, Kolarova T, Qi JW, Manivong K, Chalukya M, et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther. 2013;12:1002–15.

Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, et al. Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high-grade serous ovarian carcinoma. Cancer Res. 2021;81:4709–22.

CAS  PubMed  Article  Google Scholar 

Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18:75–87.

CAS  PubMed  Article  Google Scholar 

Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, et al. A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. 2017;23:4095–106.

CAS  PubMed  Article  Google Scholar 

Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, et al. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:465–78.

CAS  PubMed  Article  Google Scholar 

Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–61.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Konecny GE, Ozo AM, Tinker AV, Coleman RL, O’Malley DM, Maloney L, et al. Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecol Oncol. 2017;145(Suppl. 1):2.

Article  Google Scholar 

Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017;147:267–75.

CAS  PubMed  Article  Google Scholar 

Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020;38:3763–72.

CAS  PubMed  PubMed Central  Article  Google Scholar 

ClinicalTrials.gov. A study to evaluate rucaparib in patients with solid tumors and with deleterious mutations in HRR genes (LODESTAR). https://clinicaltrials.gov/ct2/show/NCT04171700. Accessed 25 Aug 2021.

ClinicalTrials.gov. A study to evaluate rucaparib in combination with other anticancer agents in patients with a solid tumor (SEASTAR). https://clinicaltrials.gov/ct2/show/NCT03992131. Accessed 25 Aug 2021.

Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol. 2016;12:1439–56.

CAS  PubMed